Back to Search
RYAN FINN, D.O.
D.O.
Student in an Organized Health Care Education/Training Program
NPI: 1417216359Individual
Specialties, Licenses & Credentials
Student in an Organized Health Care Education/Training ProgramPrimary
Student in an Organized Health Care Education/Training Program
Code: 390200000X
Research & Publications (20)
Evolution and differential expression of a vertebrate vitellogenin gene cluster.
PMID 19123940·BMC Evol Biol·2009
7-preclinical
The physiology and toxicology of salmonid eggs and larvae in relation to water quality criteria.
PMID 17316838·Aquat Toxicol·2007
6-review
Vertebrate yolk complexes and the functional implications of phosvitins and other subdomains in vitellogenins.
PMID 17314313·Biol Reprod·2007
6-review
The maturational disassembly and differential proteolysis of paralogous vitellogenins in a marine pelagophil teleost: a conserved mechanism of oocyte hydration.
PMID 17314318·Biol Reprod·2007
7-preclinical
Vertebrate vitellogenin gene duplication in relation to the "3R hypothesis": correlation to the pelagic egg and the oceanic radiation of teleosts.
PMID 17245445·PLoS One·2007
7-preclinical
In vivo oocyte hydration in Atlantic halibut (Hippoglossus hippoglossus); proteolytic liberation of free amino acids, and ion transport, are driving forces for osmotic water influx.
PMID 11821487·J Exp Biol·2002
7-preclinical
Reconstruction of the shallow vestibule edentulous mandible with simultaneous split thickness skin graft vestibuloplasty and mandibular endosseous implants for implant-supported overdentures.
PMID 19138614·J Oral Maxillofac Surg·2009
8-other
Reconfiguring or reproducing intra-professional boundaries? Specialist expertise, generalist knowledge and the 'modernization' of the medical workforce.
PMID 19201073·Soc Sci Med·2009
8-other
A phase I/II trial of trastuzumab plus erlotinib in metastatic HER2-positive breast cancer: a dual ErbB targeted approach.
PMID 19299235·Clin Breast Cancer·2009
3-trial
Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer.
PMID 19620495·J Clin Oncol·2009
2-rct
Genomic and proteomic analyses reveal non-neofunctionalized vitellogenins in a basal clupeocephalan, the Atlantic herring, and point to the origin of maturational yolk proteolysis in marine teleosts.
PMID 19174481·Mol Biol Evol·2009
7-preclinical
Phospholipid scramblases and Tubby-like proteins belong to a new superfamily of membrane tethered transcription factors.
PMID 19010806·Bioinformatics·2009
8-other
Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab.
PMID 19374603·Expert Rev Anticancer Ther·2009
6-review
DASMI: exchanging, annotating and assessing molecular interaction data.
PMID 19420069·Bioinformatics·2009
8-other
Unsaturated fatty acid regulation of cytochrome P450 expression via a CAR-dependent pathway.
PMID 18778245·Biochem J·2009
7-preclinical
Targeting vascular endothelial growth factor with the monoclonal antibody bevacizumab inhibits human hepatocellular carcinoma cells growing in an orthotopic mouse model.
PMID 18482274·Liver Int·2009
4-observational
Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer.
PMID 18955454·J Clin Oncol·2008
3-trial
The genome of the simian and human malaria parasite Plasmodium knowlesi.
PMID 18843368·Nature·2008
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1322 3RD ST SE, SUITE 240
PUYALLUP, WA 98372 - Phone
- (253) 697-1420
Quick Facts
- NPI
- 1417216359
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile